Dr. Conlon is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Building 10 CRC Room 5A22 National Cancer Institute
National Institute of Health 9000 Rockville Pike Bethesda MD
Bethesda, MD 20892Phone+1 301-402-2913Fax+1 301-402-1001
Education & Training
Rush University Medical CenterResidency, Internal Medicine, 1983 - 1987
Rush Medical College of Rush University Medical CenterClass of 1983
Certifications & Licensure
MD State Medical License 1987 - 2026
IL State Medical License 1983 - 2014- American Board of Internal Medicine Internal Medicine
Clinical Trials
- KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL) Start of enrollment: 2012 Jun 01
- Investigation of the Human Immune Response in Normal Subjects and Patients With Disorders of the Immune System and Cancer Start of enrollment: 1997 Jun 07
Roles: Contact, Principal Investigator
- Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma Start of enrollment: 2022 Nov 03
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- A phase 1 study of interleukin-15 in combination with avelumab in relapsed or refractory T-cell lymphoma.Max J Gordon, Sigrid Dubois, Bonita Bryant, Samuel Ng, Kevin Conlon
Leukemia & Lymphoma. 2024-07-01 - 5 citationsFirst-in-human phase I/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15Rα, as a single agent and in combination with spartalizumab in patients with adv...Rom Leidner, Kevin Conlon, Douglas G McNeel, Andrea Wang-Gillam, Sumati Gupta
Journal for Immunotherapy of Cancer. 2023-10-01 - 11 citationsInterleukin-15 augments NK cell-mediated ADCC of alemtuzumab in patients with CD52+ T-cell malignancies.Milos D Miljkovic, Sigrid P Dubois, Jürgen R Müller, Bonita Bryant, Elaine Ma
Blood Advances. 2023-02-14
Journal Articles
- IL-2 and IL-15 Blockade by BNZ-1, an Inhibitor of Selective Γ-chain Cytokines, Decreases Leukemic T-cell ViabilityKevin C Conlon, Thomas A Waldmann, Nature
Abstracts/Posters
- Interleukin-15 (IL-5) in Combination with Avelumab in Relapsed/Refractory Mature T-Cell MalignanciesKevin C Conlon, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Phase 1 Trial of Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocytic LeukemiaKevin C Conlon, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
